Federated Hermes Inc. Has $2.20 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Federated Hermes Inc. lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 9.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,890 shares of the biotechnology company’s stock after selling 733 shares during the quarter. Federated Hermes Inc.’s holdings in United Therapeutics were worth $2,195,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. ClariVest Asset Management LLC raised its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares during the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of United Therapeutics in the second quarter worth approximately $30,000. Innealta Capital LLC purchased a new stake in shares of United Therapeutics in the second quarter worth approximately $33,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the first quarter valued at approximately $32,000. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 63.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now directly owns 5,107 shares in the company, valued at approximately $1,626,988.06. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO James Edgemond sold 7,785 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. The disclosure for this sale can be found here. Insiders sold 110,922 shares of company stock worth $36,541,398 over the last quarter. Corporate insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

UTHR has been the topic of several recent analyst reports. TD Cowen raised their price objective on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. UBS Group boosted their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Oppenheimer increased their price objective on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. Wells Fargo & Company boosted their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the company from $310.00 to $321.00 in a report on Thursday, July 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $353.00 on Friday. The company has a market capitalization of $15.70 billion, a P/E ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The business has a fifty day simple moving average of $338.55 and a two-hundred day simple moving average of $290.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same period last year, the business posted $5.24 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. On average, analysts expect that United Therapeutics Co. will post 24.86 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.